JOIN NOW

Why not join CURE today? You already belong!

Good for bioscience in Connecticut. Good for you.
JOIN NOW

The CURE Calendar


Sep
25
Sun
The Science of Stability Conference @ Renaissance Newark Airport Hotel
Sep 25 – Sep 27 all-day
Sep
28
Wed
BioHaven Presents: Bioscience Investor Outlook: 2016 Trend Report and 2017… @ Anylan Center at Yale
Sep 28 @ 4:00 pm – 6:00 pm

Please join us and our diverse, deeply experienced panel of bioscience investors as they explain the venture capital trends of 2016 as well as discuss a look into the future as to where the capital will be flowing in 2017.  Hosted by Harry Penner, Director, CURE and moderated byDormer Stephen, Partner, Shipman & Goodwin, panelists include Christy Shaffer, General Partner, Hatteras Venture Partners, Kevin Rakin, Co-Founder of HighCape Partners, Tim Shannon, General Partner, Canaan Parters, Mark Dempster, Managing Director, Stifel, Nicolaus, Weisel and one additional panelist will lead this exciting conversation regarding bioscience investing, helping our region cultivate and advance biomedical innovation and services to support new medical advances.

Thank you to our sponsors:

    

     

   

Oct
4
Tue
Bioscience ClubhouseCT Presents: PITCH at Stamford Innovation Center – UCONN and Yale’s Collaborative to Spin Out Drug Discovery Start-Ups @ Stamford Innovation Center
Oct 4 @ 4:30 pm – 6:00 pm

The Program in Innovative Therapeutics for Connecticut’s Health, also known as PITCH, will create new biotech companies in Connecticut based on CT’s academic biomedical research. Building on significant academic infrastructure and experienced leadership bridging the worlds of academia, biopharma and venture capital, the PITCH program will educate and guide the state’s academic researchers to unlock Connecticut’s large potential for biotech/biopharma creation. In this highly collaborative endeavor, PITCH will translate Connecticut’s research into new ventures and jobs.

Host:


Dr. Froshauer is President and CEO of CURE (Connecticut United for Research Excellence, Inc.) and President of CURE Innovations, LLC.  She has spent over 27 years in biopharmaceuticals research and development. She is an experienced scientist, pharmaceutical executive, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector.   Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum.  Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars.

Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded with Yale scientists in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built an emerging pipeline of antibiotics to treat serious antibiotic-resistant bacterial infections. Prior to Rib-X, for 5 years Susan served as a member of Pfizer’s Strategic Alliance Group where she was part of a team involved in the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery.   Prior to work at Pfizer in business development.  Dr. Froshauer ran a drug discovery research lab responsible to identify new classes of antibiotics.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B. A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child’s Fellow.

Presenters:

Janie Merkel is the Director of the PITCH program and is passionate about helping academic scientists best apply technologies as part of their quests to develop new treatments for unmet medical needs, with no limits regarding the disease area or application. She leads a 12-person team of biologists and chemists at the Yale Center for Molecular Discovery at Yale University, where she has been for 10 years. University of Connecticut faculty bring major strengths to PITCH with robust life science programs and pharmaceutical development expertise. Janie was an undergraduate at Dartmouth College, earned her Ph.D. at Yale in Molecular Biophysics and Biochemistry and spent 6 years in biotechnology companies prior to joining Yale.

 

John C. Deacon, Ph.D. received his B.A. from the University of California, Berkeley, and his Ph.D. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder. As an Associate Research Scientist in the lab of Donald Engelman at Yale University, he investigates methods of targeting therapies to the acidic microenvironment of solid tumors. His invention, a platform technology that produces Tumor Activated Prodrugs (TAPs) of chemotherapeutic agents, controls drug uptake into cells, preventing these toxins from harming healthy tissues in the body. The TAP platform may offer near term solutions for reducing the side effects a wide range of cancers, and is being developed towards clinical and commercial realization with the help of PITCH.

Michael Lynes, Ph.D has served as Head of the Department of Molecular and Cell Biology at the University of Connecticut for the past four years.  He was educated at Colby College, and at the University of North Carolina, Chapel Hill where he earned his Ph.D. in Genetics, with a specialization in Immunology.  While at UCONN, he created the Flow Cytometry facility of the Biotechnology Center, and was Co-head of that facility for many years.  His research has spanned the study of genes that regulate the progression of leukemias, and the control of both normal and abnormal immune  responses.  In the course of these studies, he identified an unanticipated role in immuno-regulation for a stress response protein called metallothionein, and was able to show that this protein can be manipulated with an antibody made in his research laboratory as a therapeutic intervention for inflammatory bowel disease and Crohn’s disease.  Dr. Lynes has patents for this therapeutic intervention, and for instruments that measure in vitro cellular movement in real time and that enable thousands of simultaneous analyses of cellular behavior in a microarray format.  He was recognized with a NASA Space Act award for one of these inventions.

Sponsors:

  

                    

  

                    

Oct
5
Wed
Women SBIR Networking and Awareness Day: Engaging Women Innovators and Entrepreneurs
Oct 5 – Oct 6 all-day

2016 SBIR New England Regional Summit and special full day pre-conference event on the 5th titled:

Women SBIR Networking and Awareness Day: Engaging Women Innovators and Entrepreneurs

to be held at MIT on October 5th and 6th.

This event is part of a bold new direction for the SBIR/STTR program to engage and cultivate new innovative talent pipelines and ensure Women in STEM and Business fields are part of the conversation as well gaining equal access and opportunity to America’s Seed Fund! With our annual non-dilutive $2.5 Billion dollars in seed funding for high end commercializable science and technology R&D, we want to make sure next generation high-tech startups are growing with the help and power of other successful women led SBIR firms.

Fostering and encouraging participation from women is a key goal of the SBIR/STTR program. This pre-day conference, through immersive and interactive engagement, will seek to expand access of SBIR/STTR Funding to STEM focused Women Entrepreneurs and Principal Investigators.

A rock star lineup of speakers participating for the 2 day program include Helen Genier of iRobot, Laurie Leshin (President of WPI), Fiona Murray (Associate Dean of Innovation at MIT), Nina Tandon (CEO of EpiBone), Gia Schneider (CEO of Natel Energy), and many more… Including direct access to program managers from SBIR/STTR Funding agencies including NSF, NIH, DOE, DOT, DoEd, DOC, DoD, NASA, USDA, DHS, & EPA.

The 2 day event is FREE & Registration is now live!http://www.sbirroadtour.com/boston/register/

Oct
18
Tue
BioHaven Presents: Specialized Clinical Data Analysis Delivers Better Medical Care @ Anylan Center at Yale
Oct 18 @ 4:00 pm – 6:00 pm

Spring Care, Inc. is a digital health startup company, women- and minority-owned, that was founded in February 2016 and is based in New Haven. The company’s mission is to improve treatments for mental illness using big data. Spring’s technology is based on research from the Yale Department of Psychiatry, conducted by co-founder Adam Chekroud and Yale’s Chief Psychiatrist Dr. John Krystal, M.D. Spring provides easy-to-use mobile tools that providers and patients can use to screen for depression in the varied populations, identify treatments that are most likely to help these patients recover, and track their symptomatic outcomes over time.

Adam Chekroud, Co-founder Adam is a researcher at Yale University in the Psychology department. Adam is interested in the development and application of novel statistical approaches to the treatment of mental illness, especially Depression. For example, in collaboration with faculty in Psychiatry and Biostatistics, Adam recently developed a machine learning algorithm that accurately predicts clinical remission for a 12-week course of Citalopram, using a 5 minute questionnaire. The algorithm was published in the Lancet Psychiatry; has since been implemented by a startup company called Spring, and is currently being piloted across the country.

 

april-1April Koh, Co-founder & CEO April co-founded previous venture Spylight while on leave from Yale College and raised $5M for the company in Series-A funding. Afterwards, she spent half a year at Shazam in San Francisco before returning to Yale to complete a degree in Computer Science and Sociology.

 

 

My Gene Counsel is a digital health company that has creates electronic genetic counseling tools that allow patients and clinicians to fully understand and utilize their test results. Our systems pair with any genetic testing laboratory, are device-agnostic, and fueled by well-known, unbiased sources of cutting-edge genetic information. We partner with genetic testing laboratories, pharmaceutical companies, and consumers to provide ongoing, updating content and the latest in clinical trial opportunities.

Ellen Matloff received a B.S. in Biology from Union College in Schenectady, NY and an M.S. in Genetic Counseling from Northwestern Medical School in Chicago, IL.  She founded the Yale Cancer Genetic Counseling program, served as its Director for 18 years and was a lead plantiff in the BRCA gene patent case that went to the Supreme Court in 2013.  She is an active speaker, patient advocate and moderator of the hereditary cancer Tweetchat #GenCSM, @mygenecounsel.

 

Metrum Research Group, established in 2004, is a global leader in biomedical modeling and simulation. We have provided strategic decision making for more than 100 companies on over 300 projects. At Metrum Research Group we support our clients in advancing drug development programs by supplying them with the highest quality scientific expertise. Metrum Research Group utilizes a secure, high-performance, highly managed, distributed computing environment for all of its modeling and simulation analyses. Our workflows are systematically driven by process and yield consistent, repeatable results, all supported by a robust quality assurance program. All of our technologies are the result of significant internal investments, which continue to drive our services to the highest levels.

Marc R. Gastonguay, Ph.D., President & CEO For the last 20 years, Marc has been applying mathematical M&S techniques to problems in clinical pharmacology and drug development across industrial, government, and academic settings. Marc provides the scientific and thought leadership for MetrumRG.

Mark’s Publications: http://metrumrg.com/team/9999/01/01/marcg.html.

 

Cogstate Ltd (ASX:CGS) is a leading cognitive science company delivering software and services for the measurement of cognition in clinical trials, academic research and healthcare. Cogstate is a pioneer in commercializing rapid, reliable and highly sensitive computerised cognitive tests and provides expert support for rating scale instruments to drive higher quality outcome measures. Cogstate clients include the world’s leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships. With more than 120 employees and a global network of expert neuropsychologist consultants across 25 countries, the unique intersection of science, innovation and delivery is at the core of everything we do.

Kate Jopling, Operations Director, Clinical Trials Kate is Operations Director for Cogstate Clinical Trials. Ms. Jopling has over 11 years of experience in clinical research and pharmaceutical clinical trials. Ms. Jopling is responsible for leadership, management, oversight, and alignment of the operational functional areas within Clinical Trials, including Project Management, Data Management, Biostatistics, Scales and Rater Training, Systems Logistics, and Operational Clinical Science.

Ms. Jopling joined Cogstate in 2009 and has held positions with increasing management responsibility as Senior Clinical Project Manager,  Senior Clinical Data Manager, and most recently as Operations Manager. Prior to Cogstate, Ms. Jopling spent five years at a Clinical Trial Data Management Provider where she managed external vendor data acquisition. Her clinical trials experience includes Phases I-IV studies across numerous indications, including oncology, cardiovascular, and CNS. She is passionate about operational excellence, and strives to optimize processes while building cohesive teams, ensuring quality and timely delivery to Cogstate customers.

Thank you to our sponsors:

Serial Entrepreneur: David Scheer

Biotech Entrepreneur Kevin Rakin:
The Business of Science

A CT Bioscience Entrepreneur’s
Story: Craig M. Crews, Ph.D.

video-icon-Crews-200px

Talent Wanted/Talent Available

> Connecticut BioScience Job Listings
> BioScience Résumés

Click Here

Bioscience ClubhouseCT and Career Ladder Grant

Applications now being accepted. Get the details.
Click Here